Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0348321 (Haemophilus)
 15,372 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Cefixime was used in the treatment of 59 patients, 44 of whom had sinusitis, 9 otitis media and 6 various ENT infections. The clinical and bacteriological effectiveness of the drug could be evaluated in 44 patients and its safety in all 59 patients. The most common responsible pathogens were Haemophilus influenzae, streptococci including Streptococcus pneumoniae and various Enterobacteriaceae. In more than 50 per cent of the cases, the clinical picture was one of acute exacerbation of a chronic infection. The patients received cefixime 200 mg b.d. for a mean duration of 12 days. Clinical cure was achieved in 80 per cent. Fourteen out of 44 patients underwent surgery. Minor abdominal discomfort was reported by 15 per cent of the patients, and one discontinued therapy because of side-effects. Cefixime was effective and well tolerated. It is suitable for the treatment of ENT infections in adults, such as those treated in this study.
 ...
PMID:[Efficacy and tolerability of cefixime in the treatment of otorhinolaryngeal infections in adults]. 253 May 44

This is a case report of a patient who, while undergoing laparoscopic salpingectomy, also had removed from the peritoneal cavity the distal half of a Foley catheter left from an induced abortion 6 years previously. Lower abdominal discomfort had been complained of for several years. A Haemophilus vaginalis infection responded to tetracline therapy. At the time of laparoscopy no abnormal signs or symptoms were noted. On viewing the pelvic viscera through the laparoscope the distal half of the catheter was seen, grasped, and removed through the laparoscope. The patient later admitted having had an induced abortion. Since the removal of the foreign body the abdominal discomfort has subsided.
 ...
PMID:Removal of an unusual foreign body from the peritoneal cavity via laparoscopy: report of a case. 427 75

The efficacy, safety, and clinical utility of DU-6859a, a novel "new quinolone" antibacterial agent, were evaluated in patients with mild-to-moderate pneumonia or chronic respiratory tract infection (RTI) in a multicenter study. DU-6859a was administered orally after meals at a dose of 50 to 100mg, mainly twice daily, for 6 to 14 days. The clinical efficacy rate was 100% (26/26) for pneumonia and 89% (66/74) for chronic RTI, for an overall clinical efficacy rate of 92% (92/100). The overall eradication rate of causative organisms was 76% (42/55). Among the main causative organisms, Streptococcus pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa had eradication rates of 100% (14/14), 100% (13/13), and 27% (4/15), respectively. Side effects such as abdominal discomfort, soft stools, headache, or swelling of the face and lips were observed in 5.6% (6/107) of patients; most of these symptoms were mild. Abnormal laboratory test findings, such as elevation of glutamic-oxaloacetic transaminase and/or glutamic pyruvic transaminase, and eosinophilia, were noted in 16.5% (17/103) of patients; most of these abnormalities were mild. In conclusion, DU-6859a (50 to 100mg b.i.d.) showed excellent efficacy for pneumonia and chronic RTI without causing any severe, clinically significant adverse reactions. These findings show that DU-6859a is worthy of further clinical study for the treatment of RTI.
 ...
PMID:Preliminary report on DU-6859a for lower respiratory tract infection. 2968 65